Sam's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q1 2025
Question
An analyst from Mizuho Securities, on for Graig Suvannavejh, posed two questions about Avexitide. First, he asked if the LUCIDITY trial will include subgroup analyses based on the severity of post-bariatric hypoglycemia (PBH). Second, he inquired about potential payer restrictions or step-therapy requirements upon approval.
Answer
Co-CEO Joshua Cohen responded that the trial's primary focus is the full study population, which is already selected for frequent and severe events. He stated that step-therapy is not anticipated as there are no currently approved treatments for PBH. Co-CEO Justin Klee added that the target population already consists of patients who have failed standard care like medical nutrition therapy, which should be a key message for payers to ensure broad access.